Work

Management of dupilumab‐associated conjunctivitis in atopic dermatitis

Year: 2019
Type: article
Abstract: ) has been approved in the EU for the treatment of moderate-to-severe atopic dermatitis. By blocking IL-4 and IL-13 signaling pathways, dupilumab improves both objective signs and subjective symptoms of the disease. Blocking of the IL-4aRα subunit leads to improvement of the skin's barrier function and reduction in Th2-mediated inflammation. While the rate of adverse events on dupilumab is generally low, mild-to-moderate conjunctivitis associated with redness as well as a burning and foreign body sensation has been reported in up to 28 % of patients. Treatment options include topical corticosteroids and topical calcineurin inhibitors. The present review highlights the clinical presentation of dupilumab-associated conjunctivitis and addresses pharmacological and non-pharmacological options available for the treatment of this clinically highly relevant condition.
Language: English
Subfield: Dermatology
Field: Medicine
Open Access status: green
OpenAlex ID: W2921570767
FWCI: 7.622
Cites: 18
Cited by: 49
Related to: 10